Malignant Tumors Clinical Trial
Official title:
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
To use 18F-DCFPyL imaging agent and PET/CT to detect none prostate cancer solid malignancies and schwannoma tumors.
The purpose of this protocol is to extend our existing patient base from those with prostate cancer to those with any solid malignancy - as well as patients with schwannoma, a non-malignant solid tumor that also over-expresses GCP II. Using our first generation imaging agent, [18F]DCFBC, we have shown that we could detect GCP II in tissue specimens of patients with a variety of cancers, and vestibular schwannoma. We have also shown that GCP II may not only be present in the neovasculature of solid (non-prostate) tumors, but also reside within the tumor epithelium itself. We have shown that to be the case for melanoma, in particular. Our goal is to leverage the broad utility of our GCP II targeted imaging agents for managing other cancers. In addition to schwannoma, the cancers we intend to target include but will not be restricted to: head and neck cancer, salivary gland tumors, renal cell carcinoma, transitional cell carcinoma, colorectal cancer, gastric cancer, neuroendocrine cancer, glioblastoma, melanoma, pancreatic cancer, non-small cell lung cancer, soft tissue sarcoma, breast cancer, endometrial cancer, ovarian cancer, lymphoma and multiple myeloma. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02041871 -
Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer
|
N/A | |
Completed |
NCT03110783 -
Bioseal Dural Sealing Study BIOS-14-001
|
Phase 3 | |
Recruiting |
NCT05516914 -
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02534506 -
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
|
Phase 1 | |
Recruiting |
NCT05714748 -
Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors
|
Phase 1 | |
Recruiting |
NCT05987098 -
BBPA PET/CT in Patients With Malignant Tumors
|
N/A | |
Not yet recruiting |
NCT01092247 -
The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress
|
N/A | |
Recruiting |
NCT03160599 -
Restricted Calorie Ketogenic Diet as a Treatment in Malignant Tumors
|
N/A | |
Recruiting |
NCT04702841 -
CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors
|
Early Phase 1 | |
Completed |
NCT00165100 -
Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer
|
N/A | |
Suspended |
NCT05615974 -
A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT05293990 -
Usefulness of Gadovist-enhanced FLAIR Imaging
|
N/A | |
Completed |
NCT01509612 -
Additive Homeopathy in Cancer Patients
|
Phase 3 | |
Completed |
NCT01678690 -
An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors
|
Phase 0 | |
Suspended |
NCT06270394 -
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application
|
N/A | |
Completed |
NCT00412503 -
Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents
|
Phase 1 |